OGN
Strong BuyFull HouseAI neutralOrganon & Co. · Healthcare · United States · $3.6B cap · $35.0M/day traded
$13.77 -0.3% · close 12 Oct · scored 14 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Read our full research report on OGN (May 2026), freeReport expected 9 Nov: the next-year EPS estimate has fallen 0.6% over the last 13 weeks.
As of 14 Oct 2026, MoatMap's StockRank for Organon & Co. (OGN) is 95/100, ranked against 24,000+ stocks in 35 markets (Quality 57, Value 70, Momentum 75, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Organon sells women's health products, biosimilars and a large portfolio of established off-patent medicines. It has a new hormone-free IUD under FDA review and growth products such as VTAMA, but much of its revenue comes from older brands in steady decline, it carries heavy debt relative to its market value, and the shares hit a 52-week low after its chief executive resigned. The growth products have yet to prove they can offset the decline.
ABOUT ORGANON & CO.
Read
Organon & Co. is a global healthcare company dedicated to improving women's health and offering a portfolio of established brands across various therapeutic areas, alongside a growing biosimilars pipeline. Its competitive edge lies in a focused strategy on underserved women's health needs, leveraging a strong portfolio of trusted, established products with significant market presence globally.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.2B | 6.3B | 6.4B | 6.2B | 0.2% | 6.1B | 6.2B | 6.3B | 0.9% |
| EPS | 3.61 | 4.01 | 3.36 | 0.72 | -41.6% | 0.78 | 0.66 | 0.71 | -0.6% |
| Shares | 254.4M | 255.6M | 257.8M | 260.3M | +2.3% | 262.6M | — | — | — |
| Debt | 8.9B | 8.8B | 8.9B | 8.6B | -1.0% | 8.6B | — | — | — |
| Equity | -892.0M | -70.0M | 472.0M | 752.0M | 59.3% | — | — | — | — |
| Op CF | 858.0M | 799.0M | 939.0M | 700.0M | -6.6% | 737.0M | — | — | — |
| Inv CF | -420.0M | -260.0M | -513.0M | -390.0M | — | — | — | — | — |
| Fin CF | -433.0M | -569.0M | -368.0M | -561.0M | — | — | — | — | — |
Above its 200-day average and at its 52-week high.
Swung more than 80% of stocks we rank over the past year (65% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OGN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OGN | Organon & Co.(you) | $3.6B | 95 | Strong Buy |
| IDP.DE | Biogen Inc. | $32.9B | 84 | Strong Buy |
| BRM.DE | Bristol-Myers Squibb Company | $121.2B | 99 | Strong Buy |
| PFE.DE | Pfizer Inc. | $159.5B | 89 | Strong Buy |
| AMG.DE | Amgen Inc. | $222.5B | 95 | Strong Buy |
| GIS.DE | Gilead Sciences, Inc. | $185.7B | 79 | Buy |
| 4AB.DE | AbbVie Inc. | $486.5B | 95 | Strong Buy |
| NHC | National HealthCare Corporation | $3.5B | 92 | Strong Buy |
| AVAH | Aveanna Healthcare Holdings Inc. | $2.8B | 94 | Strong Buy |
| INDV | Indivior Pharmaceuticals, Inc. | $4.2B | 92 | Strong Buy |
Peer medians: ROE -26.1% · P/E 29.0x · Gross margin 64.4%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.